Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.

Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, Väyrynen JP, Zhao M, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, O'Reilly EM, Giannakis M, Ogino S, Jurdi A, Sharma S, Aleshin A, Shields AF, Nowak JA

Open source

DOI: 10.1001/jamaoncol.2025.5144
Published: 2026 Feb 1
Container: JAMA oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2025.5144,
  title = {Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.},
  author = {Zhang GQ and Meyerhardt JA and Shi Q and Twombly T and Pederson L and Ma C and Väyrynen JP and Zhao M and Takashima Y and Shergill A and Kumar P and Couture F and Kuebler P and Krishnamurthi S and Tan B and O'Reilly EM and Giannakis M and Ogino S and Jurdi A and Sharma S and Aleshin A and Shields AF and Nowak JA},
  year = {2026},
  journal = {JAMA oncology},
  doi = {10.1001/jamaoncol.2025.5144},
  url = {https://doi.org/10.1001/jamaoncol.2025.5144}
}

RIS

TY  - JOUR
TI  - Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.
AU  - Zhang GQ
AU  - Meyerhardt JA
AU  - Shi Q
AU  - Twombly T
AU  - Pederson L
AU  - Ma C
AU  - Väyrynen JP
AU  - Zhao M
AU  - Takashima Y
AU  - Shergill A
AU  - Kumar P
AU  - Couture F
AU  - Kuebler P
AU  - Krishnamurthi S
AU  - Tan B
AU  - O'Reilly EM
AU  - Giannakis M
AU  - Ogino S
AU  - Jurdi A
AU  - Sharma S
AU  - Aleshin A
AU  - Shields AF
AU  - Nowak JA
PY  - 2026
JO  - JAMA oncology
DO  - 10.1001/jamaoncol.2025.5144
UR  - https://doi.org/10.1001/jamaoncol.2025.5144
ER  -

APA

GQ, Z., JA, M., Q, S., T, T., L, P., C, M., JP, V., M, Z., Y, T., A, S., P, K., F, C., P, K., S, K., B, T., EM, O., M, G., S, O., A, J., S, S., A, A., AF, S., & JA, N. (2026). Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.. JAMA oncology. https://doi.org/10.1001/jamaoncol.2025.5144

Source records

pubmed · retrieved 2026-09-26T11:15:48.163Z